Literature DB >> 1430681

Ischemic cardiomyopathy: endomyocardial biopsy and ventriculographic evaluation of patients with congestive heart failure, dilated cardiomyopathy and coronary artery disease.

J M Hare1, G D Walford, R H Hruban, G M Hutchins, J W Deckers, K L Baughman.   

Abstract

OBJECTIVES: This study was designed to define clinical and pathophysiologic similarities and differences between patients with ischemic and idiopathic dilated cardiomyopathy.
BACKGROUND: Significant coronary artery disease in patients with new onset congestive heart failure due to dilated cardiomyopathy has important prognostic and therapeutic implications.
METHODS: Clinical, histologic, ventriculographic and hemodynamic features of patients with dilated cardiomyopathy who underwent coronary angiography were reviewed.
RESULTS: Patients with ischemic cardiomyopathy (n = 21) compared with those with idiopathic cardiomyopathy (n = 40) had similar presenting symptoms, durations of illness, and coronary risk factor profiles, with the exception of a greater prevalence of cigarette smoking (71% vs. 39%, p = 0.028) and male gender (100% vs. 70%, p = 0.014). Endomyocardial biopsy specimens from patients with ischemic cardiomyopathy demonstrated a greater prevalence of replacement fibrosis (48% vs. 8%, p = 0.001) and a lesser degree of histologically assessed myocyte hypertrophy (mean grade 0.5 +/- 0.7 vs. 1.3 +/- 1.3, p = 0.015). Although ventriculographically determined regional dyskinesia was present in both groups, there was a higher prevalence of two or more adjacent segments in the ischemic cardiomyopathy group (50% vs. 10%, p = 0.03). This ischemic group had hemodynamic variables associated with a worse prognosis: higher pulmonary artery wedge pressure (23 +/- 10 vs. 15 +/- 9 mm Hg, p = 0.006) and lower cardiac index (2.0 +/- 0.5 vs. 2.3 +/- 0.5 liters/min per m2, p = 0.044). Also, in this group, patients had a mean of 2.6 +/- 0.7 diseased vessels; 15 (71%) of 21 patients had triple-vessel disease and 18 (86%) of 21 had at least one occluded or suboccluded artery.
CONCLUSIONS: 1) Patients with ischemic and idiopathic cardiomyopathy may be clinically indistinguishable unless coronary angiography is performed. 2) A greater prevalence of replacement fibrosis and a lesser degree of myocardial hypertrophy in patients with ischemic cardiomyopathy may account for the greater extent of hemodynamic decompensation observed at presentation.

Entities:  

Mesh:

Year:  1992        PMID: 1430681     DOI: 10.1016/0735-1097(92)90243-g

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

Review 1.  The role of nitric oxide in the failing heart.

Authors:  W J Paulus
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

2.  [Clinical picture and differential diagnosis of cardiomyopathy and myocarditis].

Authors:  H H Sigusch; D Reinhardt; H R Figulla
Journal:  Med Klin (Munich)       Date:  1998-04-15

Review 3.  Beneficial effects of nitric oxide on cardiac diastolic function: 'the flip side of the coin'.

Authors:  W J Paulus
Journal:  Heart Fail Rev       Date:  2000-12       Impact factor: 4.214

4.  Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy.

Authors:  Muzammil Mushtaq; Darcy L DiFede; Samuel Golpanian; Aisha Khan; Samirah A Gomes; Adam Mendizabal; Alan W Heldman; Joshua M Hare
Journal:  J Cardiovasc Transl Res       Date:  2014-10-30       Impact factor: 4.132

5.  Do clinical diagnoses correlate with pathological diagnoses in cardiac transplant patients? The importance of endomyocardial biopsy.

Authors:  Adriana Luk; Mohammed Metawee; Eric Ahn; F Gustafsson; Heather Ross; Jagdish Butany
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

6.  Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction.

Authors:  Angela C Rieger; Luiza L Bagno; Alessandro Salerno; Victoria Florea; Jose Rodriguez; Marcos Rosado; Darren Turner; Raul A Dulce; Lauro M Takeuchi; Rosemeire M Kanashiro-Takeuchi; Peter Buchwald; Amarylis C B A Wanschel; Wayne Balkan; Ivonne H Schulman; Andrew V Schally; Joshua M Hare
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-26       Impact factor: 12.779

7.  Myocardial Expression Analysis of Osteopontin and Its Splice Variants in Patients Affected by End-Stage Idiopathic or Ischemic Dilated Cardiomyopathy.

Authors:  Manuela Cabiati; Benedetta Svezia; Marco Matteucci; Luca Botta; Angela Pucci; Mauro Rinaldi; Chiara Caselli; Vincenzo Lionetti; Silvia Del Ry
Journal:  PLoS One       Date:  2016-08-01       Impact factor: 3.240

8.  Genetic determinants of responsiveness to mesenchymal stem cell injections in non-ischemic dilated cardiomyopathy.

Authors:  Angela C Rieger; Robert J Myerburg; Victoria Florea; Bryon A Tompkins; Makoto Natsumeda; Courtney Premer; Aisha Khan; Ivonne H Schulman; Mayra Vidro-Casiano; Darcy L DiFede; Alan W Heldman; Raul Mitrani; Joshua M Hare
Journal:  EBioMedicine       Date:  2019-10-21       Impact factor: 8.143

9.  The impact of patient sex on the response to intramyocardial mesenchymal stem cell administration in patients with non-ischaemic dilated cardiomyopathy.

Authors:  Victoria Florea; Angela C Rieger; Makoto Natsumeda; Bryon A Tompkins; Monisha N Banerjee; Ivonne H Schulman; Courtney Premer; Aisha Khan; Krystalenia Valasaki; Bettina Heidecker; Alejandro Mantero; Wayne Balkan; Raul D Mitrani; Joshua M Hare
Journal:  Cardiovasc Res       Date:  2020-11-01       Impact factor: 10.787

10.  Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy.

Authors:  Bryon A Tompkins; Angela C Rieger; Victoria Florea; Monisha N Banerjee; Makoto Natsumeda; Evan D Nigh; Ana Marie Landin; Gianna M Rodriguez; Konstantinos E Hatzistergos; Ivonne Hernandez Schulman; Joshua M Hare
Journal:  J Am Heart Assoc       Date:  2018-07-12       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.